FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 26th, 2019 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledApril 26th, 2019 Company IndustryThis FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”), is entered into and effective as of April 26, 2019 (the “Amendment Date”) by and between ARATANA THERAPEUTICS, INC., a Delaware corporation (“Aratana”), and PACIRA PHARMACEUTICALS, INC., a California corporation (“Pacira”, together with Aratana, the “Parties”), for the purpose of amending that certain Amended and Restated Exclusive License, Development and Commercialization Agreement between Aratana and Pacira effective as of July 5, 2018 (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement, as amended.